WO2011110939A3 - Pharmaceutical compositions of substituted benzhydrylpiperazines - Google Patents

Pharmaceutical compositions of substituted benzhydrylpiperazines Download PDF

Info

Publication number
WO2011110939A3
WO2011110939A3 PCT/IB2011/000518 IB2011000518W WO2011110939A3 WO 2011110939 A3 WO2011110939 A3 WO 2011110939A3 IB 2011000518 W IB2011000518 W IB 2011000518W WO 2011110939 A3 WO2011110939 A3 WO 2011110939A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
tablets
present
substituted
cyclodextrin
Prior art date
Application number
PCT/IB2011/000518
Other languages
French (fr)
Other versions
WO2011110939A2 (en
Inventor
Pratibha Sudhir Pilgaonkar
Maharukh Tehmasp Rustomjee
Anilkumar Surendrakumar Gandhi
Original Assignee
Rubicon Research Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rubicon Research Private Limited filed Critical Rubicon Research Private Limited
Publication of WO2011110939A2 publication Critical patent/WO2011110939A2/en
Publication of WO2011110939A3 publication Critical patent/WO2011110939A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The present invention relates to pharmaceutical compositions for oral administration comprising substituted benzhydrylpiperazine, at least one cyclodextrin; and at least one polyol; wherein the substituted benzhydrylpiperazine and the cyclodextrin are present in the form of an inclusion complex. Particularly the present invention relates to stable taste- masked compositions of cetirizine, its pharmaceutically acceptable salts, its enantiomers, or their pharmaceutically acceptable salts in the form of orally disintegrating tablets, dispersible tablets, chewable tablets, effervescent tablets, or the like.
PCT/IB2011/000518 2010-03-11 2011-03-11 Pharmaceutical compositions of substituted benzhydrylpiperazines WO2011110939A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN651MU2010 2010-03-11
IN651/MUM/2010 2010-03-11

Publications (2)

Publication Number Publication Date
WO2011110939A2 WO2011110939A2 (en) 2011-09-15
WO2011110939A3 true WO2011110939A3 (en) 2012-04-26

Family

ID=44194141

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/000518 WO2011110939A2 (en) 2010-03-11 2011-03-11 Pharmaceutical compositions of substituted benzhydrylpiperazines

Country Status (1)

Country Link
WO (1) WO2011110939A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106139161A (en) * 2016-08-12 2016-11-23 合肥久诺医药科技有限公司 A kind of roflumilast clathrate and solid preparation thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102525979B (en) * 2012-02-07 2013-03-27 海南卫康制药(潜山)有限公司 Infant ibuprofen composition
KR102226833B1 (en) * 2013-06-28 2021-03-12 한미약품 주식회사 Complex granule formulation having improved stability comprising levocetirizine and montelukast
CN104666302B (en) * 2013-11-27 2017-06-30 北京韩美药品有限公司 Composition and preparation method thereof, oral liquid and preparation method thereof
CN103860462A (en) * 2014-01-14 2014-06-18 万特制药(海南)有限公司 Levocetirizine hydrochloride syrup and preparation method
CN103768031A (en) * 2014-01-16 2014-05-07 北京万全德众医药生物技术有限公司 Antiallergic pharmaceutical composition and preparation method thereof
CN103720672B (en) * 2014-01-26 2016-03-16 新疆特丰药业股份有限公司 Montelukast sodium chewable tablet and direct powder compression preparation method thereof
CN111632023A (en) * 2014-03-27 2020-09-08 Ucb法奇姆股份有限公司 Pharmaceutical composition comprising levocetirizine
JP7062368B2 (en) * 2017-03-15 2022-05-06 武田テバファーマ株式会社 Oral pharmaceutical composition masked with unpleasant taste
WO2019004776A2 (en) * 2017-06-30 2019-01-03 Hanmi Pharm. Co., Ltd. Composite chewable tablet including levocetirizine and montelukast with improved stability and drug compliance, and method of preparing the same
JP6986244B2 (en) * 2017-09-27 2021-12-22 高田製薬株式会社 Levocetirizine solid preparation
US20210386732A1 (en) * 2018-01-15 2021-12-16 Seattle Gummy Company Semi-solid anti-histamine compositions and methods of making and using thereof
BR112022015391A2 (en) * 2020-02-03 2022-10-11 Johnson & Johnson Consumer Inc SINGLE-LAYER CHEWABLE TABLET INCLUDING CETIRIZINE
US20230414597A1 (en) 2020-11-18 2023-12-28 BioPharma Synergies, S. L. Orodispersible powder composition comprising an antihistamine compound
CN114129525B (en) * 2021-10-13 2022-11-25 山东齐都药业有限公司 Meclozine orally disintegrating tablet and preparation method thereof
TR2021016324A2 (en) * 2021-10-20 2021-11-22 Ardi Farma Ilac Pazarlama Tic Ltd Sti TABLET FORMULATION FOR TASTE MASKING OF ACTIVE INGREDIENTS WITH PICTURE
CN114588123B (en) * 2022-04-13 2023-12-22 苏州中化药品工业有限公司 High-stability cetirizine hydrochloride tablet and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032217A1 (en) * 1997-07-03 2002-03-14 Domenico Fanara Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
WO2009006898A1 (en) * 2007-07-11 2009-01-15 Fertin Pharma A/S Stable medicated chewing gum comprising cyclodextrin inclusion complex
WO2009078034A2 (en) * 2007-11-26 2009-06-25 Rubicon Research Private Limited Oral disintegrating tablets of ropinirole hydrochloride
WO2009084017A2 (en) * 2007-10-10 2009-07-09 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75816C (en) 1981-02-06 1988-08-08 Ucb Sa Process for the preparation of therapeutically active 2- [4- (diphenylmethyl) -1-piperazinyl] -acetic acid or its amide
EP0811374A1 (en) 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
US20050038039A1 (en) 2002-01-15 2005-02-17 Domenico Fanara Formulations
JP2005526104A (en) 2002-04-04 2005-09-02 ファイザー・プロダクツ・インク Tasteable chewable tablets
DE602005003343T2 (en) 2004-04-12 2008-09-11 Pfizer Products Inc., Groton MEDICINAL PRODUCTS WITH HIDDEN TASTE IN BREAKING MULTIPARTICLES
BRPI0513455A (en) 2004-07-22 2008-05-06 Pfizer Prod Inc flavor masking formulation comprising the drug in a delayed dissolution form and / or cyclodextrin in an improved dissolution form
US20060127479A1 (en) 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
EP1830851A2 (en) 2004-12-06 2007-09-12 Themis Laboratories Private Limited Rapid disintegrating taste masked compositions and a process for its preparations
US9198862B2 (en) 2005-07-22 2015-12-01 Rubicon Research Private Limited Dispersible tablet composition
WO2007144902A1 (en) 2006-06-12 2007-12-21 Jubliant Organosys Limited Chewable bilayer tablet formulation
WO2008119033A1 (en) 2007-03-27 2008-10-02 Eurand, Inc. Pharmaceutical compositions comprising an active substance from the substituted benzhydrylpiperazine family
ES2564056T3 (en) 2008-09-05 2016-03-17 Johnson & Johnson Consumer Inc. Method of making cetirizine tablets

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032217A1 (en) * 1997-07-03 2002-03-14 Domenico Fanara Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
WO2009006898A1 (en) * 2007-07-11 2009-01-15 Fertin Pharma A/S Stable medicated chewing gum comprising cyclodextrin inclusion complex
WO2009084017A2 (en) * 2007-10-10 2009-07-09 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
WO2009078034A2 (en) * 2007-11-26 2009-06-25 Rubicon Research Private Limited Oral disintegrating tablets of ropinirole hydrochloride

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106139161A (en) * 2016-08-12 2016-11-23 合肥久诺医药科技有限公司 A kind of roflumilast clathrate and solid preparation thereof

Also Published As

Publication number Publication date
WO2011110939A2 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
WO2011110939A3 (en) Pharmaceutical compositions of substituted benzhydrylpiperazines
IL251662A0 (en) Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
WO2011030351A3 (en) Taste - masked pharmaceutical compositions
WO2011146876A3 (en) Oral transmucosal administration of sufentanil
WO2008089260A3 (en) Combined administration of benzonatate and guaifenesin
WO2012021715A3 (en) Stable formulations of linaclotide
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
WO2013183062A3 (en) Palatable formulations of ibuprofen
WO2012059724A8 (en) Formulations comprising polyethylene glycol
WO2011152809A3 (en) Effervescent formulations comprising cephalosporin and clavulanic acid
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2013106068A3 (en) Therapeutic compositions of specified herbal formulations and uses thereof
WO2012087255A3 (en) Pharmaceutical formulations comprising imatinib
WO2010046933A3 (en) Pharmaceutical compositions of taste-masked linezolid
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
WO2013057741A3 (en) Pharmaceutical compositions of ursodeoxycholic acid
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
WO2011064558A3 (en) Pharmaceutical composition
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
JO3587B1 (en) Oral dosage forms of bendamustine
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
IT1401284B1 (en) NEW PHARMACEUTICAL FORMULATIONS SUITABLE FOR ORAL ADMINISTRATION OF DIHYDRATE ESOMEPRAZOLE MAGNESIUM, IN THE FORM OF MUPS TABLETS (MULTI UNIT PELLETS SYSTEM).
FR2940116B1 (en) FORMULATION FOR THE ADMINISTRATION OF HYPOLIPEMIC BY ORAL TRANS-MUCOSAL
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11716027

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11716027

Country of ref document: EP

Kind code of ref document: A2